Langlara cleared as interchangeable biosimilar to Lantus

What this means

Langlara is a biosimilar version of Lantus, a long-acting insulin used to manage diabetes by helping control blood sugar levels. The FDA approved Langlara as interchangeable with Lantus, meaning pharmacists can substitute it without consulting the prescribing doctor. This decision could expand access to a lower-cost insulin option for people with diabetes who rely on long-acting insulin therapy.